

February 26, 2026
JCR Pharmaceuticals Co., Ltd.

JCR Establishes Advanced Biopharmaceutical Research Institute

Hyogo, Japan – February 26, 2026 – [JCR Pharmaceuticals Co., Ltd.](#) (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, will establish the Advanced Biopharmaceutical Research Institute at Creative Lab Kobe (CLIK) within the Kobe Biomedical Innovation Cluster (KBIC) to advance biopharmaceutical research and core technologies.

The institute will focus on addressing unmet medical needs, including neurodegenerative and rare diseases. In addition to advancing existing research and development (R&D) initiatives, it will pursue novel therapeutic strategies and innovative drug delivery technologies.

Based in the KBIC, which brings together industry, academia, and government, the institute will strengthen collaboration with academic institutions and external research organizations while developing new core technologies for future biopharmaceutical research.

Overview of the Advanced Biopharmaceutical Research Institute

Location: Creative Lab Kobe (CLIK), Rooms 601–602, 6-3-7 Minatojima-Minamimachi, Chuo-ku, Kobe, Japan

Planned Opening: April 1, 2026

Director: Kenichi Takahashi, Ph.D., Scientific Expert Fellow

About the Kobe Biomedical Innovation Cluster

Launched by the City of Kobe in 1998 as part of post Great Hanshin Awaji Earthquake reconstruction efforts, the KBIC has grown over nearly 30 years into one of Japan’s largest biomedical cluster. The area brings together academic institutions, medical companies, RIKEN research centers, advanced hospitals, and research infrastructure including the supercomputer Fugaku, creating a strong environment for biomedical research and development.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR’s global website: <https://jcrpharm.com/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###